XXXX for the management of @entity170 .

@entity1 @entity178 @entity172 @entity174 @entity170
@entity170 is a gender-related disease that is especially prevalent in postmenopausal @entity1 . New drugs have been developed led by issues of interest and concerns about this disease, each one striving to be more effective and safer than the previous one. @entity178 is a new, third-generation, selective @entity172 receptor modulator. This drug is used to treat @entity170 in @entity1 with a high risk of @entity174 . @entity178 significantly prevents bone mass loss at 20 mg/day in healthy postmenopausal @entity1 with normal or low bone mineral density. The risk of @entity174 in @entity1 with @entity170 was reduced by 42% (P < 0.05) after 3 years in a pivotal study. Five years later, the reduction was still 35% (P = 0.014). Post hoc analysis in @entity1 with a high risk of @entity174 showed a 50% reduced risk of nonvertebral @entity174 (P = 0.02) after 3 years and a 37% reduction (P = 0.06) after 5 years. @entity178 shows anti- @entity174 potential in the first few years after menopause and a greater antiestrogen effect at the level of the uterus. This has made this compound an appropriate option in young postmenopausal @entity1 with @entity170 and a risk of @entity174 .
